Please enable JS



Most Recent



50 State Network Advocate Talking Points: Non-Preferred and Specialty Tier Drugs

Jun 09/GHLF Staff / Seth's 50 State Network Talking Points

1. As patients, our core concerns are to safeguard safety and the physician-patient relationship. 2. We believe only physicians should decide if a non-preferred or specialty tier drug is right for their patients. 3. Patients should pay the same for non-preferred drugs as they do for preferred drugs when it is the best or only […]


50 State Network Advocate Brief: Non-Preferred and Specialty Tier Drugs

Jun 09/GHLF Staff / Memos Seth's 50 State Network

How can you help? Help support bills that limit patients’ costs for specialty tier drugs. 87% of stand-alone Medicare Part D Prescription Drug Plans and 98% of Medicare Advantage-Prescription Drug Plans use specialty tiers, and this can be very expensive for those in need of special medicines. Patients who need non-preferred or specialty tier drugs […]


What is research and why should you care?

Apr 21/GHLF Staff / Memos

by Ben Nowell, MSW, Ph.D.   Anyone in science or academia will tell you that the primary goal of undertaking a Ph.D. is to learn how to become a research scientist. Having recently completed a Ph.D. myself, I now feel more excited, yet more daunted than ever about scientific research and its implications. But what […]


GHLF Supports AIR 340B Hospital Charity Care Analysis

Mar 25/GHLF Staff / Memos Seth's 50 State Network

The Global Healthy Living Foundation (GHLF) is excited to announce its support for the recent release of an Alliance for Integrity and Reform of 340B (AIR 340B) hospital charity care analysis entitled “Unfulfilled Expectations: An Analysis of Charity Care provided by 340B Hospitals”. Congress created the 340B program in 1992 to help uninsured, low-income patients […]


GHLF Comments at FDA Public Arthritis Advisory Committee Meeting

Feb 10/GHLF Staff / arthritis

FDA PUBLIC HEARING STATEMENT, OPINION AND RECOMMENDATION Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee       Discussion of data and analyses published in 2006 or later that are relevant to further understanding the relationship between nonsteroidal anti-inflammatory drugs (NSAIDs) and cardiovascular thrombotic risk that is […]